OncoMatch/Clinical Trials/NCT06806033
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Is NCT06806033 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Obinutuzumab and Glofitamab for b-cell non-hodgkins lymphoma.
Treatment: Obinutuzumab · Glofitamab · Gemcitabine · Oxaliplatin — This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MYC rearrangement
DLBCL/HGBL with MYC and BCL2 rearrangements
Required: BCL2 rearrangement
DLBCL/HGBL with MYC and BCL2 rearrangements
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
At least one line of prior systemic therapy
Cannot have received: glofitamab or other bispecific antibodies targeting both CD20 and CD3
Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3
Cannot have received: gemcitabine (gemcitabine)
Prior treatment with gemcitabine or oxaliplatin
Cannot have received: oxaliplatin (oxaliplatin)
Prior treatment with gemcitabine or oxaliplatin
Cannot have received: monoclonal antibodies
Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment
Cannot have received: radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent
Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alaska Oncology & Hematology, LLC · Anchorage, Alaska
- Community Cancer Institute (CCI) · Clovis, California
- Providence Medical Foundation · Fullerton, California
- Los Angeles Cancer Network · Glendale, California
- Valkyrie Clinical Trials · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify